Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Inc.

www.amgen.com

Latest From Amgen Inc.

Advances On the Biosimilar Litigation Battlefield

A look at the evolution of litigation, from Amgen's 'bold' at-risk launch of Herceptin and Avastin biosimilars to the jump in settlements, new battles over manufacturing information and an expected petition to the Supreme Court.

Biosimilars Intellectual Property

Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi

Entrectinib clinched double approvals in the US for ROS1-positive NSCLC and for tumors with NTRK gene fusions – making it the third tumor-agnostic and second NTRK-fusion approval in the US.

Approvals Personalized Medicine

UK's AstronauTx Gets Cash For Alzheimer's Programs

The Dementia Discovery Fund is backing the UCL spin-off's efforts to develop therapies that modulate astrocyte function.

Financing Neurology

Amgen Could Block Enbrel Biosimilars For Another Decade As Court Rules Stealth Patents Valid

Court rejects Sandoz's arguments that patents covering Enbrel's active ingredient and method of manufacture are invalid; decision comes three years after FDA approved Sandoz's biosimilar.

Biosimilars Intellectual Property
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register